Humana Inc
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.88%.
Did HUM Beat Earnings? Q1 2025 Results
Humana posted a stronger-than-expected first quarter in 2025, with adjusted EPS of $11.58 clearing the $10.07 consensus estimate by 14.97%, even as revenue of $32.11 billion came in just 0.34% below expectations despite growing 8.4% year over year from $29.61 billion. The headline earnings beat was driven primarily by favorable Insurance segment performance, where a benefit ratio of 87.4% reflected the payoff from deliberate pricing actions, plan exits, and benefit redesign efforts, along with outperformance at the CenterWell health services segment and timing shifts in administrative expenses. Membership headwinds from the company's planned exit of roughly 560,000 individual Medicare Advantage members were partly cushioned by premium increases tied to IRA direct subsidies and growth in stand-alone PDP and state-based contracts. The results arrive as sector-wide anxiety around Medicare Advantage medical cost trends has intensified following a dramatic earnings collapse at a major industry peer. Humana affirmed full-year 2025 adjusted EPS guidance of approximately $16.25 and consolidated revenue guidance of $126 billion to $128 billion, signaling confidence despite an ongoing MA membership repositioning.
- Higher per-member Medicare and state-based contract premiums driven by increased direct subsidy from the Inflation Reduction Act
- Membership growth in stand-alone PDP and state-based contracts businesses
- Individual Medicare Advantage pricing inclusive of plan exits, benefit design changes, and favorable workday impacts improving benefit ratio
- CenterWell outperformance driven by primary care growth and stabilizing medical cost trends
- Administrative cost efficiencies from value creation initiatives
- Favorable prior period medical claims reserve development of $477 million (160 bps benefit ratio improvement)
- CenterWell Primary Care patient growth of 27,300 (7% sequential) including 16% growth in de novo centers
“Our team has done a great job launching us on a strong start to the year. Medicare Advantage is performing as expected and we are excited about our progress in expanding CenterWell and Medicaid.”
Humana CEO, on the earnings call
Forward Guidance & Outlook
Humana affirmed its full-year 2025 Adjusted EPS guidance of 'approximately $16.25' while revising GAAP EPS guidance to 'approximately $14.68' from 'approximately $15.88'. The company affirmed consolidated revenue guidance of $126 billion to $128 billion, Insurance segment revenue of $121 billion to $123 billion, and CenterWell segment revenue of $20.5 billion to $21.5 billion. Insurance segment benefit ratio guidance of 90.1% to 90.5% was reaffirmed. Individual Medicare Advantage membership is expected to decline approximately 550,000 for the full year, while stand-alone PDP membership is expected to grow approximately 200,000 and state-based contracts membership to grow 175,000 to 250,000. Full-year operating cash flows are projected at $2.4 billion to $2.9 billion with capital expenditures of approximately $650 million. Second quarter earnings are expected to be approximately 35% of full-year 2025 Adjusted earnings, with Q2 Insurance segment benefit ratio expected to be approximately 90%. The company continues to target individual MA pretax margin of 'at least 3%' over time and anticipates 'a few hundred million dollars' of incremental investments in 2025. The 2026 final MA rate notice is viewed positively as better reflecting the medical cost trend environment. An Investor Conference is planned for June 16, 2025 to discuss mid- and longer-term outlook.
HUM YoY Financials
HUM Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.